AVXL - Anavex Life Sciences Corp.
NEXT EARNINGS:
May 12, 2026
EPS Est: $-0.07
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$11.00
DETAILS
HIGH:
$11.00
LOW:
$11.00
MEDIAN:
$11.00
CONSENSUS:
$11.00
UPSIDE:
152.29%
Market Cap:
404.05M
Volume:
999,221
Avg Volume:
1,957,175
52 Week Range:
2.86-13.99
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.07
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
42
IPO Date:
2006-08-02
EPS (TTM):
-0.54
P/E Ratio:
-16.37
Revenue (TTM):
N/A
Total Assets:
103.81M
Total Debt:
N/A
Cash & Equiv:
102.58M
Rev Growth (5Y):
-100.0%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-48.9%
Debt/Equity:
N/A
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-09 | $-0.06 | $-0.10 | +40.0% | — | — | — |
| 2025-11-25 | $-0.11 | $-0.13 | +15.4% | — | — | — |
| 2025-08-12 | $-0.16 | $-0.13 | -23.1% | — | — | — |
| 2025-05-13 | $-0.13 | $-0.16 | +18.8% | — | — | — |
| 2025-02-12 | $-0.14 | $-0.17 | +17.6% | — | — | — |
| 2024-12-23 | $-0.14 | $-0.17 | +17.6% | — | — | — |
| 2024-08-06 | $-0.14 | $-0.15 | +6.7% | — | — | — |
| 2024-05-09 | $-0.13 | $-0.13 | 0.0% | — | — | — |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | (685,000) | 0 | 0 | 0 | 0 | 0 |
| Net Income | (46.38M) | (43.00M) | (47.51M) | (47.98M) | (37.91M) | (26.28M) | (26.30M) | (17.45M) | (13.46M) | (14.74M) | (12.11M) | (11.37M) |
| EPS | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 | -0.45 | -0.54 | -0.39 | -0.33 | -0.42 | -0.65 | -1.16 |
| Total Assets | 103.81M | 135.57M | 154.39M | 152.70M | 161.62M | 34.54M | 25.33M | 24.38M | 27.84M | 9.50M | 15.47M | 7.35M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 85,570 | 5.91M |
| Cash & Equivalents | 102.58M | 132.19M | 151.02M | 149.16M | 152.11M | 29.25M | 22.19M | 22.93M | 27.44M | 9.19M | 15.29M | 7.26M |
| Operating Cash Flow | (39.04M) | (30.81M) | (27.79M) | (24.24M) | (30.38M) | (21.29M) | (18.53M) | (12.58M) | (9.02M) | (9.24M) | (4.23M) | (2.66M) |
| Free Cash Flow | (39.04M) | (30.81M) | (27.79M) | (24.24M) | (30.38M) | (21.29M) | (18.53M) | (12.58M) | (9.02M) | (9.24M) | (4.23M) | (2.66M) |
| FCF per Share | -0.46 | -0.37 | -0.35 | -0.32 | -0.44 | -0.37 | -0.38 | -0.28 | -0.22 | -0.26 | -0.23 | -0.27 |
| Book Value | 94.87M | 120.26M | 141.85M | 142.49M | 150.82M | 27.24M | 20.29M | 20.49M | 24.25M | 6.31M | 12.81M | 192,626 |
| Cash & ST Investments | 102.58M | 132.19M | 151.02M | 149.16M | 152.11M | 29.25M | 22.19M | 22.93M | 27.44M | 9.19M | 15.29M | 7.26M |
| ROC Equity | -0.49 | -0.36 | -0.33 | -0.34 | -0.25 | -0.96 | -1.30 | -0.85 | -0.55 | -2.34 | -0.95 | -59.02 |